Research

Hormonal

Targeting the Ghrelin Receptor (GHSR1a) with inverse agonists or antagonists like LEAP2 reduces food intake and postprandial glucose, offering a potential treatment for type-2 diabetes and obesity.

A new approach to blocking hunger involves a natural peptide called LEAP2. In a small study, giving LEAP2 intravenously reduced how much people ate and lowered their blood sugar after meals. This suggests it might help people with type-2 diabetes or obesity, but more research is needed to see if these benefits last long-term.

ModerateSupportsMEDIUM confidence
a recent small clinical trial in 20 healthy individuals showed that intravenous administration of LEAP2 could successfully reduce food intake, meal duration and postprandial glucose, presenting the possibility that LEAP2 could be of clinical utility in type-2 diabetes and obesity
Aqfan Jamaluddin et al. · Journal of Molecular Endocrinology · 2023

Why this rating

Based on a small clinical trial (n=20) and pre-clinical data; long-term effects and efficacy in diabetic/obese patients need further validation.

Source

RISING STARS: Targeting G protein-coupled receptors to regulate energy homeostasis

Aqfan Jamaluddin et al. · Journal of Molecular Endocrinology · 2023

DOI 10.1530/jme-23-0014

narrative_reviewCited 12×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →